v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash Flows From Operating Activities    
Net loss $ (16,001) $ (8,152)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,911 2,580
Interest accretion 331 248
Reversal of DOJ accrual (350)
Bad debt expense 499
Mark to market on warrants (35) 259
Stock-based compensation 1,246 1,564
Other gains and expenses, net 18
Other changes in operating assets and liabilities:    
Increase in accounts receivable (1,986) (2,703)
Increase in other current assets (417) (174)
Increase in long-term assets (11)
(Decrease) increase in accounts payable (766) 674
Increase (decrease) in accrued salaries and bonus 228 (248)
Increase (decrease) in accrued liabilities 981 (680)
Increase in long-term liabilities 446 182
Net cash used in operating activities (12,556) (6,800)
Cash Flows From Investing Activity    
Acquisition of Biopharma, net of expenses (13,829)
Purchase of property and equipment (105) (388)
Sale of property and equipment 13
Net cash used in investing activity (13,921) (388)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 5,962
Issuance of preferred shares, net of expenses 13,087
Cash paid for repurchase of restricted shares (32) (9)
Borrowings on Line of Credit 3,750
Net cash provided by (used in) financing activities 22,767 (9)
Net decrease in cash and cash equivalents (3,710) (7,197)
Cash and cash equivalents - beginning 6,068 15,199
Cash and cash equivalents - ending $ 2,358 $ 8,002

Source